Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Analysis of p53Gene Mutations in Keloids Using Polymerase Chain Reaction–Based Single-Strand Conformational Polymorphism and DNA Sequencing—Clinical Implications

Analysis of p53Gene Mutations in Keloids Using Polymerase Chain Reaction–Based Single-Strand... 3. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS. Reduced growth- 18. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation factor requirement of keloid derived fibroblasts may account for tumor growth. by adenovirus early 1B protein. Nature. 1992;357:82-85. Proc Natl Acad SciUSA. 1988;85:587-591. 19. Debbas M, White E. Wild type p53 mediates apoptosis by E1A, which is inhib- 4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of ited by E1B. Genes Dev. 1993;71:546-554. p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304- 20. Moran E. Interaction of adenoviral proteins with pRB and p53. FASEB J. 1993; 6311. 7:880-885. 5. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the ge- 21. Momand J, Xambetti GP, Olson DC, George DL, Levine AJ. The mdm-2 onco- nomic instability of cancer cells. Cell. 1992;71:543-546. gene product forms a complex with the p53 protein and inhibits p53 mediated 6. Lane DP. p53: guardian of the genome. Nature. 1992;358:15-16. transactivation. Cell. 1992;69:1237-1245. 7. Unger T, Nau MN, Segal S, Minna JD. p53: a transdominant regulator of tran- 22. Oliner JD, Kinzler KW, Meitzer PS, Georges DL, Vogelstein B. Amplification http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Analysis of p53Gene Mutations in Keloids Using Polymerase Chain Reaction–Based Single-Strand Conformational Polymorphism and DNA Sequencing—Clinical Implications

JAMA Dermatology , Volume 134 (8) – Aug 1, 1998

Analysis of p53Gene Mutations in Keloids Using Polymerase Chain Reaction–Based Single-Strand Conformational Polymorphism and DNA Sequencing—Clinical Implications

Abstract

3. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS. Reduced growth- 18. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation factor requirement of keloid derived fibroblasts may account for tumor growth. by adenovirus early 1B protein. Nature. 1992;357:82-85. Proc Natl Acad SciUSA. 1988;85:587-591. 19. Debbas M, White E. Wild type p53 mediates apoptosis by E1A, which is inhib- 4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW....
Loading next page...
 
/lp/american-medical-association/analysis-of-p53gene-mutations-in-keloids-using-polymerase-chain-twzfjivkRC
Publisher
American Medical Association
Copyright
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.134.8.967
Publisher site
See Article on Publisher Site

Abstract

3. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS. Reduced growth- 18. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation factor requirement of keloid derived fibroblasts may account for tumor growth. by adenovirus early 1B protein. Nature. 1992;357:82-85. Proc Natl Acad SciUSA. 1988;85:587-591. 19. Debbas M, White E. Wild type p53 mediates apoptosis by E1A, which is inhib- 4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of ited by E1B. Genes Dev. 1993;71:546-554. p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304- 20. Moran E. Interaction of adenoviral proteins with pRB and p53. FASEB J. 1993; 6311. 7:880-885. 5. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the ge- 21. Momand J, Xambetti GP, Olson DC, George DL, Levine AJ. The mdm-2 onco- nomic instability of cancer cells. Cell. 1992;71:543-546. gene product forms a complex with the p53 protein and inhibits p53 mediated 6. Lane DP. p53: guardian of the genome. Nature. 1992;358:15-16. transactivation. Cell. 1992;69:1237-1245. 7. Unger T, Nau MN, Segal S, Minna JD. p53: a transdominant regulator of tran- 22. Oliner JD, Kinzler KW, Meitzer PS, Georges DL, Vogelstein B. Amplification

Journal

JAMA DermatologyAmerican Medical Association

Published: Aug 1, 1998

There are no references for this article.